Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 2,800 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,800 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $105,420.00. Following the completion of the transaction, the chief operating officer now owns 262,660 shares of the company’s stock, valued at $9,889,149. The trade was a 1.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, April 23rd, Patrick John Finn sold 2,058 shares of Twist Bioscience stock. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42.
• On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The shares were sold at an average price of $38.73, for a total transaction of $7,978.38.

Twist Bioscience Price Performance

TWST stock opened at $30.82 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $30.72 and a 12 month high of $60.90. The stock has a market cap of $1.85 billion, a PE ratio of -9.12 and a beta of 2.54. The company has a 50-day moving average price of $38.63 and a 200 day moving average price of $43.65.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

TWST has been the subject of a number of research analyst reports. Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday. Barclays reduced their price objective on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. Guggenheim reiterated a “buy” rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.40.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC increased its stake in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares during the period. Avanza Fonder AB bought a new stake in shares of Twist Bioscience during the fourth quarter valued at approximately $1,059,000. Principal Financial Group Inc. raised its stake in shares of Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after acquiring an additional 82,953 shares in the last quarter. Vanguard Group Inc. grew its stake in Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after purchasing an additional 189,791 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company’s stock worth $1,761,000 after purchasing an additional 9,722 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.